格拉斯哥预后评分在血液系统恶性肿瘤中的预后价值：一项系统评价和荟萃分析
Prognostic value of Glasgow prognostic score in hematological malignancies: a systematic review and meta-analysis.
作者信息
Jiang Lijun, Jin Wenting
机构信息
Departments of Hematology, The Affiliated Hospital of Jiaxing University, No. 1882 Zhonghuan South Road, Nanhu District, Jiaxing, 314000, Zhejiang, China.
出版信息
Int J Hematol. 2025 Apr;121(4):450-461. doi: 10.1007/s12185-025-03935-z. Epub 2025 Feb 3.
OBJECTIVE
The Glasgow prognostic score (GPS) is used to predict the prognosis of several cancers. This first systematic review and meta-analysis evaluated the role of GPS in predicting overall survival (OS) and progression-free survival (PFS) in patients with hematological malignancies.
METHODS
Embase, PubMed, CENTRAL, Scopus, and Google Scholar were screened for studies evaluating the prognostic role of GPS in hematological malignancies.
RESULTS
Twelve studies were eligible. Meta-analysis showed that patients with GPS of ≥1 and ≥2 had worse OS than those with GPS of 0. We noted that both GPS scores of ≥1 and ≥2 were associated with significantly poor PFS in patients with hematological malignancies. Results remained robust on sensitivity analysis.
CONCLUSION
GPS can be used as a predictor of OS and PFS in patients with hematological malignancies. High GPS scores can lead to a twofold higher risk of poor OS and PFS.
目的
格拉斯哥预后评分（GPS）用于预测多种癌症的预后。本项首次系统评价和荟萃分析评估了GPS在预测血液系统恶性肿瘤患者总生存期（OS）和无进展生存期（PFS）方面的作用。
方法
检索Embase、PubMed、CENTRAL、Scopus和谷歌学术，查找评估GPS在血液系统恶性肿瘤中预后作用的研究。
结果
12项研究符合条件。荟萃分析显示，GPS≥1和≥2的患者的OS比GPS为0的患者更差。我们注意到，GPS≥1和≥2均与血液系统恶性肿瘤患者的PFS显著较差相关。敏感性分析结果依然可靠。
结论
GPS可作为血液系统恶性肿瘤患者OS和PFS的预测指标。高GPS评分可导致OS和PFS不良风险增加两倍。
Zotero 插件